Tebapivat by Agios Pharmaceuticals for Sickle Cell Disease: Likelihood of Approval

Tebapivat is under clinical development by Agios Pharmaceuticals and currently in Phase I for Sickle Cell Disease.

Michigan bill that would pare back pharma liability shield law moves closer to enactment

A one-of-a-kind law in Michigan that prevents the state government and residents from suing pharmaceutical companies over injuries caused by their medicines is poised to

November 13, 2023

FDA proposes reclassifying hepatitis B assays

Dive Brief: The Food and Drug Administration has proposed changing antigen, antibody and nucleic acid-based hepatitis B virus (HBV) assays to a lower-risk classification. Currently, the

September 26, 2024

Racial and ethnic disparities in surgical outcomes cost lives

About 12,000 Black and Hispanic patients who died after surgery the past two decades may have lived if there were no racial and ethnic disparities

October 16, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.